🚗 🚙 Turn your trusty old car into trustworthy journalism Learn more

Lexapro’s incredible tax-dodging journey

Stacey Vanek Smith May 14, 2010
HTML EMBED:
COPY

Lexapro’s incredible tax-dodging journey

Stacey Vanek Smith May 14, 2010
HTML EMBED:
COPY

Corporations will sometimes go to great lengths to avoid paying taxes. Is it worth it? Reporter Jesse Drucker explores this idea in a Bloomberg article following the money from the sale of a bottle of anti-depressant Lexapro.

The journey beings with a $99 bottle of Lexapro sold to someone in Phoenix, Ariz. Drucker found that $85 of the purchase ends up with New York City-based Forrest Laboratories, which makes the drug. But the majority of the profits then travel to Ireland, where Forrest makes the pills at a manufacturing facility that enjoys low taxes. The company then makes licensing payments to a subsidiary of itself in Bermuda, which has no corporate income tax, shifting a majority of the income out of Ireland into Bermuda.

Forrest earned nearly a billion dollars in pre-tax income in 2009, and spends in the low millions to save about $200 million on taxes.

There’s a lot happening in the world.  Through it all, Marketplace is here for you. 

You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible. 

Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.